Is the cost of research aimed at curing HIV worth it, when HIV can be effectively managed and prevented by existing drugs?

Mathematical models indicate that the worst-case scenario of the Trump administration’s HIV-related cuts could result in 3 ...

Serious concerns continue to mount over the impact of HIV in Fiji, as eight children were among the 126 people who died from ...

The COVID-19 pandemic paused many HIV prevention efforts, which helped fuel last year's rise in new infections. President Donald Trump's federal funding cuts threaten to further hamper those efforts.

Lenacapavir, the injectable drug developed by a US-based company, Gilead Sciences, was trialled (tested) in Uganda and South ...

The 'Silence=Death' poster from the early years of the AIDS crisis holds true today with the possibility of federal cuts to ...

Low screening coverage, late diagnoses, high HIV prevalence, and limited access to treatment and vaccines are driving cervical cancer cases and deaths in South Africa. The country has a cervical ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

Lenacapavir has demonstrated enormous potential as a new HIV prevention tool with a 100 per cent efficacy rate and zero ...

Steep cuts to the US Agency for International Development threaten to cause more than 14mn extra deaths by 2030 and reverse ...

If there’s one person in Cebu City who can walk the talk in raising HIV awareness and eliminating its stigma, it’s Shun ...